RichardHHaubrichMD
Internal Medicine • San Diego, CAInfectious Disease
Professor, Medicine, University of California San Diego School of Medicine
Are you Dr. Haubrich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
Mail Code 8208
San Diego, CA 92103Phone+1 619-543-8080Fax+1 619-298-0177
Summary
- Dr. Richard Haubrich, MD is a board certified internist in San Diego, California. He is currently licensed to practice medicine in California. He is affiliated with UC San Diego Medical Center - Hillcrest and is a Professor at University of California San Diego School of Medicine.
Education & Training
UMass Chan Medical SchoolFellowship, Infectious Disease, 1987 - 1990
Scripps Mercy HospitalResidency, Internal Medicine, 1983 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1983
Certifications & Licensure
CA State Medical License 1984 - 2026- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir Start of enrollment: 2004 Dec 07
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.Dahlene Fusco, Ivana Malenica, Huldrych F Günthard, Samir K Gupta, Dax Kurbegov
Clinical Infectious Diseases. 2024-11-22 - Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year.Stefan Esser, Alexy Inciarte, Itzchak Levy, Antonella D'Arminio Monforte, John S Lambert
Future Microbiology. 2024-01-01 - 1 citationsClinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19.Nadir Arber, Pallav L Shah, Lambert Assoumou, Casper Rokx, Nathalie De Castro
Infectious Diseases Now. 2023-10-01
Grant Support
- Improving Antiretroviral Management For HIVNational Institute Of Allergy And Infectious Diseases2006–2012
- Clinical InvestigationNational Institute Of Allergy And Infectious Diseases2007–2011
- Assessing The Clinical Consequences Of HIV Drug ResistanceNational Institute Of Allergy And Infectious Diseases2008–2009
- ACTG A5142 Lopinavir/Ritonavir PLUS Efavirenz For HIV -1 InfectionNational Center For Research Resources2007
- ACTG A5079 Physiologic Testosterone Supplementation In HIVNational Center For Research Resources2005–2006
- ACTG A5142 Lopinavir/Ritonavir PLUS Efavirenz For HIV-1 InfectionNational Center For Research Resources2004–2006
- ACTG A5079 Physiologic Testosterone Supplements In HIVNational Center For Research Resources2004
